C07K 14/70517
Cd8
Official title: {cd8}
C07K14/70517 (Cd8) appears on 784 US grants and 1,708 published applications in this corpus.
Search patents in C07K- Granted patents
- 784
- Published applications
- 1,708
- Assignees
- 596
- Inventors
- 2,848
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 3 |
| 2004 | 0 | 1 |
| 2005 | 0 | 4 |
| 2006 | 1 | 1 |
| 2007 | 0 | 2 |
| 2008 | 2 | 1 |
| 2009 | 1 | 2 |
| 2010 | 0 | 2 |
| 2011 | 2 | 1 |
| 2012 | 0 | 4 |
| 2013 | 1 | 8 |
| 2014 | 3 | 16 |
| 2015 | 10 | 17 |
| 2016 | 11 | 36 |
| 2017 | 15 | 55 |
| 2018 | 10 | 90 |
| 2019 | 36 | 133 |
| 2020 | 86 | 176 |
| 2021 | 84 | 224 |
| 2022 | 102 | 210 |
| 2023 | 83 | 183 |
| 2024 | 118 | 221 |
| 2025 | 117 | 185 |
| 2026 | 86 | 133 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Chimeric cytokine receptors and methods of use thereof1 Oct 2026US 2026/0294970 A1Legend Biotech USA Inc.
- Chimeric antigen receptor targeting bcma and use thereof1 Oct 2026US 2026/0295044 A1Shenzhen Cell Valley Biomedical Co., Ltd.
- Chimeric polypeptides, extracellular vesicles comprising the same, and uses thereof1 Oct 2026US 2026/0295068 A1Ciloa
- High-affinity t cell receptor for identifying kras mutation and use thereof1 Oct 2026US 2026/0297159 A1Xlifesc, Ltd.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014
- Compositions for treatment of cancer199US 8,975,071 B1The Trustees of the University of Pennsylvania · 2015